GSK (GSK -2.7%) withdraws a supplemental New Drug Application to the FDA to use its Tykerb drug...


GSK (GSK -2.7%) withdraws a supplemental New Drug Application to the FDA to use its Tykerb drug in combination with Genentech's Herceptin for the treatment of a certain type of breast cancer in patients who have already received Herceptin. "Our discussions with FDA highlighted questions that could not be addressed with the data currently available," GSK says.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs